Detailed Information

Cited 121 time in webofscience Cited 117 time in scopus
Metadata Downloads

Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer

Authors
Jansen, Valerie M.Bhola, Neil E.Bauer, Joshua A.Formisano, LuigiLee, Kyung minHutchinson, Katherine E.Witkiewicz, Agnieszka K.Moore, Preston D.Estrada, Monica ValeriaSanchez, VioletaEricsson, Paula G.Sanders, Melinda E.Pohlmann, Paula R.Pishvaian, Michael J.Riddle, David A.Dugger, Teresa C.Wei, WenyiKnudsen, Erik S.Arteaga, Carlos L.
Issue Date
May-2017
Publisher
AMER ASSOC CANCER RESEARCH
Citation
CANCER RESEARCH, v.77, no.9, pp.2488 - 2499
Indexed
SCIE
SCOPUS
Journal Title
CANCER RESEARCH
Volume
77
Number
9
Start Page
2488
End Page
2499
URI
https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/142837
DOI
10.1158/0008-5472.CAN-16-2653
ISSN
0008-5472
Abstract
Acquired resistance to cyclin-dependent kinases 4 and 6 (CDK4/6) small-molecule inhibitors in breast cancer arises through mechanisms that are yet uncharacterized. In this study, we used a kinome-wide siRNA screen to identify kinases that, when downregulated, yield sensitivity to the CDK4/6 inhibitor ribociclib. In this manner, we identified 3-phosphoinositide-dependent protein kinase 1 (PDK1) as a key modifier of ribociclib sensitivity in estrogen receptor–positive MCF-7 breast cancer cells. Pharmacologic inhibition of PDK1 with GSK2334470 in combination with ribociclib or palbociclib, another CDK4/6 inhibitor, synergistically inhibited proliferation and increased apoptosis in a panel of ER-positive breast cancer cell lines. Ribociclib-resistant breast cancer cells selected by chronic drug exposure displayed a relative increase in the levels of PDK1 and activation of the AKT pathway. Analysis of these cells revealed that CDK4/6 inhibition failed to induce cell-cycle arrest or senescence. Mechanistic investigations showed that resistant cells coordinately upregulated expression of cyclins A, E, and D1, activated phospho-CDK2, and phospho-S477/T479 AKT. Treatment with GSK2334470 or the CDK2 inhibitor dinaciclib was sufficient to reverse these events and to restore the sensitivity of ribociclib-resistant cells to CDK4/6 inhibitors. Ribociclib, in combination with GSK2334470 or the PI3Kα inhibitor alpelisib, decreased xenograft tumor growth more potently than each drug alone. Taken together, our results highlight a role for the PI3K–PDK1 signaling pathway in mediating acquired resistance to CDK4/6 inhibitors.
Files in This Item
Go to Link
Appears in
Collections
서울 자연과학대학 > 서울 생명과학과 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Lee, Kyung min photo

Lee, Kyung min
COLLEGE OF NATURAL SCIENCES (DEPARTMENT OF LIFE SCIENCE)
Read more

Altmetrics

Total Views & Downloads

BROWSE